Develop a Fit-for-Purpose Potency Assay from Translation through to QC,
that Meets Complex Regulatory Expectations, by Defining Relevant
Measurement Parameters and Advancing Novel Technologies
Your Must-Attend Meeting to Advance Your
Potency Assay Strategy
The inaugural Cell Therapy Potency Assay Summit is the first and only industry defining forum set to address the complexity of measuring potency as the most pressing cause of regulatory delay for cell therapeutics.
Cell therapies are poised to emerge as game changing in oncology and beyond however the FDA has often delayed approvals and clinical advancements due to the intricacy associated with measuring potency, often stating that the data provided is insufficient.
This timely forum will unite experts across analytical development, quality, regulatory and process development to brainstorm best-in-class approaches to overcome variability in QC, compare next gen approaches from cytotoxicity to omics, develop reference standards to benchmark across the industry, and create an assay with commercialization in mind.
This summit will equip you with the tools you need to fast track your regulatory submissions and ease through clinical development.
This event is CPD Certified, meaning that delegates can get an official Continuing Professional Development certificate by attending.
Testimonials from the 2021 Cell Therapy Analytical Development Summit:
“A breakthrough summit that enables a discussion on emerging needs in the analytical development area”
Scientist, CRISPR Therapeutics
“It is a fantastic get-together for analytical, CMC, QC and process development experts”
Manager, Bristol Myers Squibb
2022’s World Class Speaker Faculty Includes
2022’s Partners Include: